Progressive Muscular Atrophy (Pma) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Progressive muscular atrophy (PMA), also known as Duchenne–Aran disease, is a rare variant of [Motor Neuron Disease[/diseases/[motor-neuron-disease[/diseases/[motor-neuron-disease[/diseases/[motor-neuron-disease[/diseases/[motor-neuron-disease--TEMP--/diseases)--FIX-- (MND) characterized by progressive degeneration of lower
motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (LMNs) in the spinal cord and [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--, resulting in generalized, progressive muscle weakness, wasting, and fasciculations without clinically evident upper motor
neuron (UMN) signs. PMA occupies a controversial position within the Motor [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- Disease spectrum: while historically classified as a distinct entity, pathological studies reveal
that the majority of PMA cases harbor subclinical UMN degeneration and [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--/proteins/tdp-43) proteinopathy indistinguishable from [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- [2], leading many experts to consider PMA a predominantly LMN phenotype of ALS rather than a separate disease.
PMA accounts for approximately 2.5–11% of adult-onset MND cases and predominantly affects men (male-to-female ratio up to 5:1), with a mean onset age below 50 years [1] [5].
- Proportion of MND: PMA represents approximately 2.5–11% of all adult-onset Motor Neuron Disease cases.
- Incidence: Due to its rarity and diagnostic variability, precise incidence data are limited. Estimates range from 0.02–0.04 per 100,000 person-years in population-based studies.
- Sex: Strong male predominance with a male-to-female ratio of approximately 4–5:1 (compared to ~1.5:1 in classic ALS).
- Age at onset: Typically in the 5th–6th decade, though onset can range from the 3rd to 8th decade. Mean age at onset is approximately 50 years.
- Geographic distribution: No clear geographic clustering, though ascertainment varies by diagnostic criteria used.
Autopsy studies have been pivotal in understanding PMA's relationship to [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--. A landmark study of 962 patients at the ALS Center at [Columbia University[/institutions/[columbia[/institutions/[columbia[/institutions/[columbia[/institutions/[columbia--TEMP--/institutions)--FIX-- [2] [3].
- [Protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX--: Accumulation of ubiquitinated inclusions in anterior horn cells.
- Selective [motor neuron vulnerability]: Preferential degeneration of alpha motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the ventral horn of the [spinal cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord--TEMP--/brain-regions)--FIX--, with relative sparing of oculomotor and Onuf's nucleus [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--.
- [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--: Elevated markers of oxidative damage in degenerating motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- [3] [7].
- [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--: Activated [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia mutations**: Rare cases of PMA have been associated with [SOD1)[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX-- mutations, particularly those associated with LMN-predominant ALS phenotypes (e.g., A4V, D90A).
- [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX--: Hexanucleotide repeat expansion in [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- has been identified in some PMA patients, particularly those with LMN-predominant presentations and FTD features.
- [FUS[/entities/[fus[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX--: Mutations occasionally associated with PMA phenotype, especially in younger-onset cases with basophilic inclusion body disease.
- [TARDBP[/genes/[tardbp[/genes/[tardbp[/genes/[tardbp[/genes/[tardbp--TEMP--/genes)--FIX--: Rare [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- mutations reported in PMA phenotypes.
- SMN1/SMN2: Must be excluded in cases with slowly progressive LMN disease, as [spinal muscular atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy--TEMP--/diseases)--FIX-- can mimic PMA.
Genetic testing is recommended for all PMA patients, particularly for [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX--, [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX--, and [SMN1[/genes/[smn1[/genes/[smn1[/genes/[smn1[/genes/[smn1--TEMP--/genes)--FIX-- as clinically indicated.
PMA presents with progressive, painless muscle weakness and wasting that typically begins in the distal upper extremities (hands) and spreads proximally and to other limbs:
- Muscle atrophy: Progressive wasting, often first noted in the intrinsic [hand[/diseases/[hand[/diseases/[hand[/diseases/[hand[/diseases/[hand--TEMP--/diseases)--FIX-- muscles (thenar and hypothenar eminence atrophy, interossei)
- Fasciculations: Visible involuntary muscle twitching, widespread and persistent, often one of the earliest features
- Weakness: Progressive, initially focal, spreading to involve multiple limb segments and eventually axial muscles
- Muscle cramps: Painful cramps, particularly in the calves and hands, often preceding noticeable weakness
- Hypotonia and areflexia: Reduced muscle tone and absent or diminished deep tendon reflexes, reflecting LMN pathology
- Pattern of spread: Usually begins asymmetrically in the upper limbs, then spreads contralaterally and to lower limbs. The "split hand" sign (preferential thenar > hypothenar wasting) may be present as in ALS.
- Less common at presentation than in classic ALS
- When present: dysarthria (slurred, nasal speech), dysphagia, tongue atrophy and fasciculations, facial weakness
- Bulbar onset is rare in PMA but carries a worse prognosis
| Feature |
PMA |
Classic ALS |
| UMN signs |
Absent (clinically) |
Present (spasticity, hyperreflexia, Babinski) |
| Progression rate |
Slower |
Faster |
| Male predominance |
Strong (4–5:1) |
Moderate (1.5:1) |
| Median survival |
~5+ years |
~3 years |
| Conversion to ALS |
~20–30% develop UMN signs |
— |
| Neuropathology |
Most have subclinical UMN degeneration |
Overt UMN + LMN degeneration |
Longitudinal studies demonstrate that approximately 20–30% of patients initially diagnosed with PMA develop clinically evident UMN signs within 5 years, effectively meeting criteria for ALS. This "phenotypic conversion" underscores the concept that PMA represents one end of a clinical spectrum rather than a discrete entity. Regular clinical monitoring for emergent UMN signs (spasticity, hyperreflexia, extensor plantar responses) is essential.
PMA is a diagnosis of exclusion — there is no single confirmatory test. Diagnosis requires:
- Evidence of progressive LMN dysfunction in multiple body regions
- Absence of clinically apparent UMN signs
- Exclusion of other causes of LMN disease (Spinal Muscular Atrophy, multifocal motor neuropathy, Kennedy's disease, post-polio syndrome, spinal cord compression)
- Electrodiagnostics (EMG/NCS): EMG shows widespread active and chronic denervation (fibrillations, positive sharp waves, fasciculation
potentials, large motor unit potentials, reduced recruitment) across multiple body regions. Motor nerve conduction studies show reduced
CMAP amplitudes with preserved conduction velocities (distinguishing from demyelinating neuropathies). [Nerve conduction
studies[/diagnostics/[emg-nerve-conduction[/diagnostics/[emg-nerve-conduction[/diagnostics/[emg-nerve-conduction[/diagnostics/[emg-nerve-conduction--TEMP--/diagnostics)--FIX-- are essential [9].
- MRI of brain and spinal cord: To exclude structural causes (cervical myelopathy, spinal cord tumors, syringomyelia). Brain MRI is typically normal (no corticospinal tract signal changes seen in some ALS cases).
- Blood tests: Anti-GM1 antibodies (exclude multifocal motor neuropathy with conduction block), [genetic testing[/diagnostics/[genetic-testing[/diagnostics/[genetic-testing[/diagnostics/[genetic-testing[/diagnostics/[genetic-testing--TEMP--/diagnostics)--FIX-- (SMN1 for SMA, SOD1, [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX--, CK (often mildly elevated), vitamin B12, copper, lead levels.
- Muscle biopsy: Rarely needed; shows neurogenic atrophy pattern (grouped fiber atrophy, fiber type grouping).
- CSF analysis: [NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX--/proteins/nfl (neurofilament light chain) is often elevated, reflecting axonal degeneration, though lower than in classic ALS.
- [Kennedy's disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease--TEMP--/diseases)--FIX-- (SBMA): X-linked; androgen receptor CAG repeat expansion; gynecomastia, sensory neuropathy
- [spinal muscular atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy--TEMP--/diseases)--FIX--: SMN1 mutations; earlier onset; symmetric proximal weakness
- Multifocal motor neuropathy (MMN): Anti-GM1 antibodies; conduction block on NCS; treatable with IVIg [1] [5].
- 5-year survival: ~56% of PMA patients are alive 5 years after diagnosis, compared to ~14% of ALS patients <a href="#ref-1" class="ref-link" data-ref-number="1" data-ref-text="Visser J, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol. 2007;64(4):522-528. . . DOI
- 10-year survival: ~25–30% of PMA patients.
- Prognostic factors: Older age at onset, bulbar involvement, and rapid early decline predict shorter survival. Conversion to ALS phenotype (development of UMN signs) is associated with worse outcome.
- Cause of death: Respiratory failure from diaphragm and respiratory muscle weakness is the primary cause of death, as in ALS.
- [Amyotrophic Lateral Sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- | [Primary Lateral Sclerosis[/diseases/[primary-lateral-sclerosis[/diseases/[primary-lateral-sclerosis[/diseases/[primary-lateral-sclerosis[/diseases/[primary-lateral-sclerosis--TEMP--/diseases)--FIX--
- [Motor [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- Disease] | [Kennedy's Disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease--TEMP--/diseases)--FIX--
- [spinal muscular atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy[/diseases/[spinal-muscular-atrophy--TEMP--/diseases)--FIX-- | [spinal cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord--TEMP--/brain-regions)--FIX--
- [TDP-43[/proteins/[tdp-43[/proteins/[tdp-43[/proteins/[tdp-43[/proteins/[tdp-43--TEMP--/proteins)--FIX-- | [TDP-43 Proteinopathy[/mechanisms/[tdp-43-proteinopathy[/mechanisms/[tdp-43-proteinopathy[/mechanisms/[tdp-43-proteinopathy[/mechanisms/[tdp-43-proteinopathy--TEMP--/mechanisms)--FIX--
- [Motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--/cell-types/motor-[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- | [Selective Neuronal Vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability--TEMP--/mechanisms)--FIX--
- [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX-- | [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- | [FUS[/entities/[fus[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX--
- [Riluzole[/treatments/[riluzole[/treatments/[riluzole[/treatments/[riluzole[/treatments/[riluzole--TEMP--/treatments)--FIX-- | [Edaravone[/treatments/[edaravone[/treatments/[edaravone[/treatments/[edaravone[/treatments/[edaravone--TEMP--/treatments)--FIX--
- [EMG and Nerve Conduction Studies[/diagnostics/[emg-nerve-conduction[/diagnostics/[emg-nerve-conduction[/diagnostics/[emg-nerve-conduction[/diagnostics/[emg-nerve-conduction--TEMP--/diagnostics)--FIX--
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
The study of Progressive Muscular Atrophy (Pma) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The University of Southern California (USC) conducts comprehensive research on neurodegenerative diseases through multiple centers and institutes.
¶ Memory and Aging Research
- [Alzheimer]'s Disease Research Center
- LonDownS Consortium (Down syndrome and Alzheimer's)
- Loneliness and social isolation studies
- Institute for Neuroimaging and Informatics
- Center for BrainHealth
- Stem cell research programs
- Early detection and prevention
- Biomarker development
- Therapeutic interventions
- Population studies
USC hosts leading researchers in:
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- genetics
- Neuroimaging
- Clinical trials
- Public health
USC participates in numerous Alzheimer's and related dementia clinical trials through its research centers.
-
Alzheimer's Association
-
National Institute on Aging
-
California Department of Public Health
-
[Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
-
[University of California[/institutions/[ucsf[/institutions/[ucsf[/institutions/[ucsf[/institutions/[ucsf--TEMP--/institutions)--FIX--
-
[Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
-
USC Alzheimer's Disease Research Center
-
USC Institute for Neuroimaging
- USC Alzheimer's Disease Research Center publications
- NIH grant documentation
- Research collaborations
- [Visser J, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol. 2007;64(4]:522-528. . . DOI
- [Kim WK, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009;73(20]:1686-1692. . . DOI
- [Ince PG, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol. 2011;122(6]:657-671. . . DOI
- [Riku Y, et al. Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. BMJ Open. 2014;4(5]:e005213. . . DOI
- [van den Berg-Vos RM, et al. Outcome and diagnosis in a large cohort of patients with isolated lower motor neuron syndromes. J Neurol. 2013;260(7]:1188-1195. . . DOI
- [Nardo G, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6(10]:e25545. . . DOI
- [Turner MR, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(S1]:19-32. . . DOI
- [Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. . . DOI
- [de Carvalho M, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3]:497-503. . . DOI
- [Garg N, et al. Differentiating lower motor neuron syndromes. J Neurol Neurosurg Psychiatry. 2017;88(6]:474-483. . . DOI